Big On - thank you very much for such a quick response. Agree with most of what you had to say - and can respect your discretion - particularly in the Bavi vs Avastin arena - FYI - in the "as well as" vs "better" discussion - we are hearing the latter from several directions. Re Dr. Garnick - again in concurrance - everyone who has talked with him reports him demonstrating a great deal of enthusiasm and genuine excitement.
We'll look for the BioSimilars PR. Thanks for the heads-up.
BOT, thanks for your updates. We had heard last December that a phIII trial for Bavi cancer would commence in April. Have you heard if that's still on track, or if it has been slid?
Thanks for your update. I’m very interested in Avid’s potential in the biosimilars market. It's an opportunity that’s on the opposite side of the scale with regards to risk as compared to PPHM’s other activities. This, if promoted, has the potential to attract a different type of investor and open the door for more readily available funding.
News 
Market Data 
Discover 
AI
